Science

Bisantrene is a small molecule anti-cancer drug which has potential as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. History of Bisantrene Bisantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracyclines. Lederle trialled Bisantrene on a wide range of cancers in the 1980s (more than 40 clinical trials) and it showed particular promise in leukemias, breast cancer and ovarian cancer. Bisantrene was studied in a large Phase III breast cancer trial in the late…

Latest News

+

Race updates its Three Pillar Strategy, detailing intended programs and activitiesThe update confirms progress on all Three Pillars, and shares…

Race enters a collaborative preclinical research program with The University of Newcastle to support the use of Bisantrene in the…

Race enters a collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel…